Can We Predict In-Hospital Mortality After TAVR?

A new risk prediction model from a national database improves the selection of patients.

Transcatheter aortic valve replacement (TAVR) is approved for high-risk surgical patients and is under investigation for lower-risk candidates. Using data from the American College of Cardiology/Society of Thoracic Surgeons Transcatheter Valve Therapy (TVT) Registry covering >13,000 patients undergoing TAVR in the U.S., investigators designed and tested a risk model to predict in-hospital mortality, with the goal that clinicians could use the model to improve patient-centric care.

The development dataset included 13,718 TVT records of procedures performed between 2011 and 2014 at 265 sites. The model was tested with a subsequent validation sample of 6868 procedures from 314 sites in 2014. Covariates used in the final model were age, renal fu…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)